vs
APOGEE ENTERPRISES, INC.（APOG）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
APOGEE ENTERPRISES, INC.的季度营收约是Orthofix Medical Inc.的1.6倍（$351.4M vs $219.9M），APOGEE ENTERPRISES, INC.净利率更高（4.7% vs -1.0%，领先5.7%），Orthofix Medical Inc.同比增速更快（2.0% vs 1.6%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.9%）
Apogee Enterprises是一家美国音频设备制造商，主营音频接口、模数与数模转换器、USB及iOS麦克风，同时还开发音频制作相关软件，产品广泛服务于专业录音、音乐创作等音频领域，在全球音频行业拥有较高的认可度。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
APOG vs OFIX — 直观对比
营收规模更大
APOG
是对方的1.6倍
$219.9M
营收增速更快
OFIX
高出0.4%
1.6%
净利率更高
APOG
高出5.7%
-1.0%
两年增速更快
OFIX
近两年复合增速
2.9%
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $351.4M | $219.9M |
| 净利润 | $16.6M | $-2.2M |
| 毛利率 | 22.4% | 71.1% |
| 营业利润率 | 7.3% | 0.2% |
| 净利率 | 4.7% | -1.0% |
| 营收同比 | 1.6% | 2.0% |
| 净利润同比 | 568.8% | 92.4% |
| 每股收益（稀释后） | $0.78 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APOGOFIX
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | $219.9M | ||
| Q3 25 | $358.2M | $205.6M | ||
| Q2 25 | $346.6M | $203.1M | ||
| Q1 25 | $345.7M | $193.6M | ||
| Q4 24 | $341.3M | $215.7M | ||
| Q3 24 | $342.4M | $196.6M | ||
| Q2 24 | $331.5M | $198.6M |
净利润APOGOFIX
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | $-2.2M | ||
| Q3 25 | $23.6M | $-22.8M | ||
| Q2 25 | $-2.7M | $-14.1M | ||
| Q1 25 | $2.5M | $-53.1M | ||
| Q4 24 | $21.0M | $-29.1M | ||
| Q3 24 | $30.6M | $-27.4M | ||
| Q2 24 | $31.0M | $-33.4M |
毛利率APOGOFIX
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 71.1% | ||
| Q3 25 | 23.1% | 72.2% | ||
| Q2 25 | 21.7% | 68.7% | ||
| Q1 25 | 21.6% | 62.8% | ||
| Q4 24 | 26.1% | 69.0% | ||
| Q3 24 | 28.4% | 68.7% | ||
| Q2 24 | 29.8% | 67.8% |
营业利润率APOGOFIX
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | 0.2% | ||
| Q3 25 | 7.5% | -8.3% | ||
| Q2 25 | 2.0% | -7.9% | ||
| Q1 25 | 1.8% | -25.2% | ||
| Q4 24 | 8.4% | -5.3% | ||
| Q3 24 | 12.3% | -9.6% | ||
| Q2 24 | 12.5% | -12.5% |
净利率APOGOFIX
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | -1.0% | ||
| Q3 25 | 6.6% | -11.1% | ||
| Q2 25 | -0.8% | -6.9% | ||
| Q1 25 | 0.7% | -27.4% | ||
| Q4 24 | 6.1% | -13.5% | ||
| Q3 24 | 8.9% | -13.9% | ||
| Q2 24 | 9.4% | -16.8% |
每股收益（稀释后）APOGOFIX
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | $-0.05 | ||
| Q3 25 | $1.10 | $-0.57 | ||
| Q2 25 | $-0.13 | $-0.36 | ||
| Q1 25 | $0.12 | $-1.35 | ||
| Q4 24 | $0.96 | $-0.76 | ||
| Q3 24 | $1.40 | $-0.71 | ||
| Q2 24 | $1.41 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.5M | $82.0M |
| 总债务越低越好 | $232.3M | — |
| 股东权益账面价值 | $511.8M | $450.0M |
| 总资产 | $1.1B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资APOGOFIX
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | $82.0M | ||
| Q3 25 | $39.5M | $62.9M | ||
| Q2 25 | $32.8M | $65.6M | ||
| Q1 25 | $41.4M | $58.0M | ||
| Q4 24 | $43.9M | $83.2M | ||
| Q3 24 | $51.0M | $30.1M | ||
| Q2 24 | $30.4M | $26.4M |
总债务APOGOFIX
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | $285.0M | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益APOGOFIX
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | $450.0M | ||
| Q3 25 | $500.2M | $442.5M | ||
| Q2 25 | $481.8M | $458.3M | ||
| Q1 25 | $487.9M | $458.3M | ||
| Q4 24 | $522.1M | $503.1M | ||
| Q3 24 | $506.4M | $525.9M | ||
| Q2 24 | $480.0M | $546.0M |
总资产APOGOFIX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $850.6M | ||
| Q3 25 | $1.2B | $832.6M | ||
| Q2 25 | $1.2B | $837.2M | ||
| Q1 25 | $1.2B | $823.1M | ||
| Q4 24 | $1.2B | $893.3M | ||
| Q3 24 | $917.1M | $867.9M | ||
| Q2 24 | $889.0M | $882.0M |
负债/权益比APOGOFIX
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | 0.58× | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $122.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | 7.8% | 4.9% |
| 现金转化率经营现金流/净利润 | 7.37× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流APOGOFIX
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $27.7M | ||
| Q3 25 | $57.1M | $12.4M | ||
| Q2 25 | $-19.8M | $11.6M | ||
| Q1 25 | $30.0M | $-18.4M | ||
| Q4 24 | $31.0M | $23.7M | ||
| Q3 24 | $58.7M | $11.7M | ||
| Q2 24 | $5.5M | $9.0M |
自由现金流APOGOFIX
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $16.8M | ||
| Q3 25 | $52.4M | $2.5M | ||
| Q2 25 | $-26.9M | $4.5M | ||
| Q1 25 | $19.1M | $-25.1M | ||
| Q4 24 | $22.0M | $15.2M | ||
| Q3 24 | $50.2M | $6.3M | ||
| Q2 24 | $-1.8M | $-360.0K |
自由现金流率APOGOFIX
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 7.6% | ||
| Q3 25 | 14.6% | 1.2% | ||
| Q2 25 | -7.8% | 2.2% | ||
| Q1 25 | 5.5% | -13.0% | ||
| Q4 24 | 6.4% | 7.0% | ||
| Q3 24 | 14.7% | 3.2% | ||
| Q2 24 | -0.5% | -0.2% |
资本支出强度APOGOFIX
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 4.9% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 2.1% | 3.5% | ||
| Q1 25 | 3.2% | 3.5% | ||
| Q4 24 | 2.6% | 4.0% | ||
| Q3 24 | 2.5% | 2.7% | ||
| Q2 24 | 2.2% | 4.7% |
现金转化率APOGOFIX
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.08× | — | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
